TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis.
It has long been recognized that insults to the cerebral cortex, such as trauma, ischaemia or infections, may result in the development of epilepsy, one of the most common neurological disorders. Human and animal studies have suggested that perturbations in neurovascular integrity and breakdown of the blood-brain barrier (BBB) lead to neuronal hypersynchronization and epileptiform activity, but the mechanisms underlying these processes are not known. In this study, we reveal a novel mechanism for epileptogenesis in the injured brain. We used focal neocortical, long-lasting BBB disruption or direct exposure to serum albumin in rats (51 and 13 animals, respectively, and 26 controls) as well as albumin exposure in brain slices in vitro. Most treated slices (72%, n = 189) displayed hypersynchronous propagating epileptiform field potentials when examined 5-49 days after treatment, but only 14% (n = 71) of control slices showed similar responses. We demonstrate that direct brain exposure to serum albumin is associated with albumin uptake into astrocytes, which is mediated by transforming growth factor beta receptors (TGF-betaRs). This uptake is followed by down regulation of inward-rectifying potassium (Kir 4.1) channels in astrocytes, resulting in reduced buffering of extracellular potassium. This, in turn, leads to activity-dependent increased accumulation of extracellular potassium, resulting in facilitated N-methyl-d-aspartate-receptor-mediated neuronal hyperexcitability and eventually epileptiform activity. Blocking TGF-betaR in vivo reduces the likelihood of epileptogenesis in albumin-exposed brains to 29.3% (n = 41 slices, P < 0.05). We propose that the above-described cascade of events following common brain insults leads to brain dysfunction and eventually epilepsy and suggest TGF-betaRs as a possible therapeutic target.
Ivens
Sebastian
S
Institute of Neurophysiology, Charité University Medicine, Berlin, Germany.
Kaufer
Daniela
D
Flores
Luisa P
LP
Bechmann
Ingo
I
Zumsteg
Dominik
D
Tomkins
Oren
O
Seiffert
Ernst
E
Heinemann
Uwe
U
Friedman
Alon
A
D000818:Animals; D001253:Astrocytes / Q000378:metabolism*; D001812:Blood-Brain Barrier / Q000503:physiopathology; D004195:Disease Models, Animal; D015536:Down-Regulation; D004569:Electroencephalography; D004827:Epilepsy / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology*; D008279:Magnetic Resonance Imaging; D019579:Neocortex / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D009474:Neurons / Q000502:physiology; D011188:Potassium / Q000378:metabolism; D024661:Potassium Channels, Inwardly Rectifying / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D018125:Receptors, Transforming Growth Factor beta / Q000502:physiology*; D012709:Serum Albumin / Q000493:pharmacokinetics* / Q000633:toxicity; D046509:Tissue Culture Techniques; D000098854:Kcnj10 Channel
D000098854:Kcnj10 Channel; D024661:Potassium Channels, Inwardly Rectifying; D018125:Receptors, Transforming Growth Factor beta; D012709:Serum Albumin; D011188:Potassium